Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cladribine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 44 for your search:
Start Over
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL04, NCT00199017
Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SAKK 32/98, SWS-SAKK-32/98, EU-98074, NCT00003746
Phase I/II Study of Cladribine Plus Interferon in Patients with Advanced Low Grade Lymphoid Malignancies (Summary Last Modified 03/2000)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NU-93H4, NCI-G99-1635
Phase I/II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Adults with Acute Nonlymphoblastic Leukemia (Summary Last Modified 05/98)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 17 and over
Sponsor:
Protocol IDs: MSKCC-91094, NCI-V91-0185
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000619329, NCCTG-N078D, N078D, NCT00787969
Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Progressive or Recurrent Malignant Glioma (Summary Last Modified 05/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: UCCRC-7154, NCI-V94-0451
Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Residual and Recurrent Primary CNS Malignancies (Summary Last Modified 05/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: MSKCC-94038, NCI-V94-0475
Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Hairy Cell Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: SWS-SAKK-32/93, EU-94037
Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) by 2-Hour Infusion for Previously Untreated B-Cell Chronic Lymphocytic Leukemia (Summary Last Modified 05/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NU-LE94-52-005, NCI-V95-0666
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: under 22
Sponsor: NCI, Other
Protocol IDs: 2951, CCG-2951, CDR0000064907, NCT00002805
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 55 to 70
Sponsor: NCI, Other
Protocol IDs: DM94-078, P30CA016672, MDA-DM-94078, NCI-G96-1001, CDR0000065035, NCT00002833
Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Relapsed or Refractory Acute Myeloid Leukemia (Summary Last Modified 05/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: E-5995, E5995
Cladribine in Patients With Mantle Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065179, NCCTG-958053, NCT00002879
Phase II Study of Sequential Cyclophosphamide/Prednisone and Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-958151, NCCTG-95-81-51
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: Under 21 at diagnosis
Sponsor: NCI, Other
Protocol IDs: 9720, COG-P9720, POG-9720, CDR0000065993, NCT00003178
Phase II Study of Cladribine with Cyclophosphamide and Prednisone in Patients with B Cell Chronic Lymphocytic Leukemia or Low Grade Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18-75
Sponsor:
Protocol IDs: SWS-SAKK-37/95, EU-97040
Phase II Study of Low Dose Bolus Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Patients with Recurrent or Newly Diagnosed Hairy Cell Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: SWS-SAKK-32/95, EU-97039
Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Patients with Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor:
Protocol IDs: MDA-DM-88083, NCI-V89-0246
Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Advanced Stage, Previously Untreated, Low-Grade Lymphomas
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: CLB-9153, CALGB-9153
Phase II Trial of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Patients with B-Cell CLL Who Have Failed Fludarabine Phosphate Therapy
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CLB-9211, CALGB-9211
Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Patients with Recurrent Glioma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-937251, NCCTG-93-72-51
Start Over